Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.GLYC · Entity 5255 | Director | May 01, 2024 | May 01, 2024 |
| MACROGENICS INCMGNX · Entity 6104 | Director | May 19, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date May 01, 2024 · Filed May 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2034-04-30 | Direct | 40,000 |
Reported balance
After 2024-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-01 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.
MACROGENICS INC
Report date May 19, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,750 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 3,750 · Balance 3,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2036-05-19 | Direct | 22,000 |
Reported balance
After 2026-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-19 · Grant · Acquired 22,000 · Balance 22,000 F3: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F2: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
F3: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
APPLIED GENETIC TECHNOLOGIES CORP
Report date November 30, 2022 · Filed December 01, 2022
Section 16 reporting ended · disclosed 2022-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Other · Disposed 34,246 · Balance 0 F1: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2023-09-18 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-30 · Disposition to issuer · Disposed 14,285 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2024-03-26 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-30 · Disposition to issuer · Disposed 9,375 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.83 · Expires 2024-12-29 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-30 · Disposition to issuer · Disposed 4,688 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.06 · Expires 2025-11-19 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-30 · Disposition to issuer · Disposed 6,200 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.75 · Expires 2027-02-28 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-30 · Disposition to issuer · Disposed 8,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2028-07-25 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2028-11-15 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2029-12-04 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2030-12-16 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-11-30 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.17 · Expires 2031-11-30 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-11-30 · Disposition to issuer · Disposed 14,000 · Balance 0 F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.
F2: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2020 Filed Dec 18, 2020 17:10 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001273636-20-000007 · edgar.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over one year from the date of grant. Read SEC document |
| May 22, 2020 Filed May 27, 2020 20:31 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032308 · doc4.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The shares underlying this option vest on May 22, 2021, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 20:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 133,163 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001125345-20-000044 · wf-form4_158413051474478.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,163 shares Expires 2022-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 20:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 133,163 | $0.94 | $125,173.22 |
DisclosureSEC source: 0001125345-20-000044 · wf-form4_158413051474478.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The transaction represents an exercise and hold of options. The shares are jointly owned with reporting person's spouse. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:45 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 290,000 | $11.50 Strike: $11.50 | $3,335,000.00 |
DisclosureSEC source: 0001125345-20-000022 · wf-form4_158258073276662.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2030-02-20 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 17:39 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001273636-19-000041 · edgar.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-12-04 F1 · derivative.exercise_date: The option becomes exercisable on December 4, 2020. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:04 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Exercise / conversionStock Option (right to buy) · Derivative | 32,018 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001273636-19-000012 · edgar.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,018 shares Expires 2023-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:04 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Exercise / conversionCommon Stock | 32,018 | $0.35 | $11,206.30 |
DisclosureSEC source: 0001273636-19-000012 · edgar.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2019 Filed May 21, 2019 20:08 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $12.39 | $0.00 |
DisclosureSEC source: 0001209191-19-031720 · doc4.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares underlying this option vest on May 17, 2020, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 21:00 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 260,000 | $0.00 Strike: $21.88 | $0.00 |
DisclosureSEC source: 0001125345-19-000027 · wf-form4_155112842141714.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2029-02-21 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 21:29 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 39,897 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001125345-19-000002 · wf-form4_154663732415783.xml · derivative · entry 4 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,897 shares Expires 2019-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction represents an exercise and hold of expiring options. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 21:29 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 39,897 | $0.94 | $37,503.18 |
DisclosureSEC source: 0001125345-19-000002 · wf-form4_154663732415783.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 19:18 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001273636-18-000063 · edgar.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-11-15 F1 · derivative.exercise_date: The option becomes exercisable on November 15, 2019. Read SEC document |
| November 13, 2018 Filed Nov 14, 2018 21:32 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001125345-18-000101 · wf-form4_154223111325336.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,897 Underlying: Common Stock · 40,000 shares Expires 2019-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction represents an exercise and hold of expiring options. Read SEC document |
| November 13, 2018 Filed Nov 14, 2018 21:32 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 40,000 | $0.94 | $37,600.00 |
DisclosureSEC source: 0001125345-18-000101 · wf-form4_154223111325336.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 17:37 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001273636-18-000028 · edgar.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2028-07-25 F1 · derivative.exercise_date: The option becomes exercisable on July 25, 2019. Read SEC document |
| July 25, 2018 Filed Jul 30, 2018 21:15 UTC Amendment | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001273636-18-000038 · edgar.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-07-25 F1 · shares: This Form 4 is being amended to correct a scrivener's error with regards to the number of shares underlying the option grant. F2 · derivative.exercise_date: The option becomes exercisable on July 25, 2019. F1 · derivative.underlying_shares: This Form 4 is being amended to correct a scrivener's error with regards to the number of shares underlying the option grant. Read SEC document |
| May 18, 2018 Filed May 21, 2018 20:17 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001209191-18-031825 · doc4.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The shares underlying this option vest on May 18, 2019, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 22:23 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 225,000 | $0.00 Strike: $28.94 | $0.00 |
DisclosureSEC source: 0001125345-18-000042 · wf-form4_152037499084075.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-03-02 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| May 25, 2017 Filed May 30, 2017 20:09 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001209191-17-036120 · doc4.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: The shares underlying this option vest on May 25, 2018, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 20:09 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0001209191-17-020152 · doc4.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2027-03-09 F1 · derivative.exercise_date: This option grant was made pursuant to the issuer's non-employee director compensation policy. The shares underlying this option vest in three equal installments on March 9, 2018, 2019 and 2020, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 19:19 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $7.75 | $0.00 |
DisclosureSEC source: 0000899243-17-006160 · doc4.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-02-28 F1 · derivative.exercise_date: Option becomes exercisable on February 28, 2018. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:44 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantCommon Stock · Derivative | 200,000 | $0.00 Strike: $20.53 | $0.00 |
DisclosureSEC source: 0001125345-17-000030 · wf-form4_148728507322958.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:40 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 79,898 | $0.94 Strike: $0.94 | $75,104.12 |
DisclosureSEC source: 0001125345-17-000003 · wf-form4_148486200205855.xml · derivative · entry 4 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,898 shares Expires 2017-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:40 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 79,898 | $0.94 | $75,104.12 |
DisclosureSEC source: 0001125345-17-000003 · wf-form4_148486200205855.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2016 Filed Jan 19, 2017 21:40 UTC | MACROGENICS INC MGNX · Entity 6104 | OtherCommon Stock | 34,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-17-000004 · wf-form5_148486201690358.xml · nonDerivative · entry 4 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Scott Koenig Family Irrevocable Trust Disclosed balance after: 167,782 F2 · kind: (2) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/18/16 was $21.06 per share. F2 · price: (2) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/18/16 was $21.06 per share. Read SEC document |
| May 18, 2016 Filed Jan 19, 2017 21:40 UTC | MACROGENICS INC MGNX · Entity 6104 | OtherCommon Stock | 34,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-17-000004 · wf-form5_148486201690358.xml · nonDerivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,265 F2 · kind: (2) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/18/16 was $21.06 per share. F2 · price: (2) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/18/16 was $21.06 per share. Read SEC document |
| May 17, 2016 Filed Jan 19, 2017 21:40 UTC | MACROGENICS INC MGNX · Entity 6104 | OtherCommon Stock | 79,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-17-000004 · wf-form5_148486201690358.xml · nonDerivative · entry 3 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Scott Koenig Family Irrevocable Trust Disclosed balance after: 167,782 F1 · kind: (1) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/17/16 was $18.04 per share. F1 · price: (1) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/17/16 was $18.04 per share. Read SEC document |
| May 17, 2016 Filed Jan 19, 2017 21:40 UTC | MACROGENICS INC MGNX · Entity 6104 | OtherCommon Stock | 79,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-17-000004 · wf-form5_148486201690358.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,265 F1 · kind: (1) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/17/16 was $18.04 per share. F1 · price: (1) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/17/16 was $18.04 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.